milnacipran + risperidone

Milnacipran + risperidone is a combination therapy involving two distinct pharmaceutical agents. Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) primarily used for the treatment of major depressive disorder and fibromyalgia. Risperidone is an atypical antipsychotic indicated for schizophrenia, bipolar disorder, and irritability associated with autistic disorder. The combination has been studied as an augmentation strategy in patients with major depression who have shown inadequate response to milnacipran monotherapy, particularly in treatment-refractory cases. The rationale behind this combination lies in targeting both serotonergic/noradrenergic pathways (via milnacipran) and dopaminergic/serotonergic receptor antagonism (via risperidone), potentially providing synergistic effects for difficult-to-treat depression[1][3][5].